[go: up one dir, main page]

IE20001017A1 - Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route - Google Patents

Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route

Info

Publication number
IE20001017A1
IE20001017A1 IE20001017A IE20001017A IE20001017A1 IE 20001017 A1 IE20001017 A1 IE 20001017A1 IE 20001017 A IE20001017 A IE 20001017A IE 20001017 A IE20001017 A IE 20001017A IE 20001017 A1 IE20001017 A1 IE 20001017A1
Authority
IE
Ireland
Prior art keywords
matrix tablet
tablet according
trimetazidine
matrix
percentage
Prior art date
Application number
IE20001017A
Inventor
De Barochez Bruno Huet
Claude Dauphant
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9553398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE20001017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of IE20001017A1 publication Critical patent/IE20001017A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a matrix tablet enabling the prolonged release of trimetazidine, or an addition salt thereof with a pharmaceutically acceptable acid, after administration by the oral route, characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer.

Description

The present invention relates to a matrix tablet enabling the prolonged release of trimetazidine, or an addition salt thereof with a pharmaceutically acceptable acid, after administration by the oral route.
Trimetazidine, or l-(2,3,4-trimethoxybenzyl)piperazine, is a compound which, by maintaining the energy metabolism of a cell exposed to hypoxia or ischaemia, avoids the collapse of the intracellular level of adenosine triphosphate (ATP). It thus ensures functioning of the ion pumps and sodium-potassium transmembrane flows and maintains cellular homeostasis.
Trimetazidine dihydrochloride is currently used therapeutically for the prophylactic treatment of angina pectoris crisis, in chorioretinal attacks and for the treatment of vertigo of vascular origin (Meniere's vertigo, tinnitus).
Trimetazidine dihydrochloride has, until now, been administered by the oral route at doses of from 40 to 60 mg/day, in the form of tablets containing 20 mg of active ingredient or a drinkable solution containing 20 mg of active ingredient per ml. Those two forms are immediate-release forms. Patent FR 2 490 963 describes the immediate-release tablet form. Trimetazidine dihydrochloride is rapidly absorbed and eliminated by the body, its plasma half-life being less than 6 hours, which means that administration of the active ingredient has to be split into 2 or 3 administrations per day in order to ensure sufficient plasma levels. The dosage regimen most frequently required during treatments is three tablets per day. Multiple daily administrations bear the risk of being forgotten both by patients leading an active life and by elderly patients already taking a number of medications.
Because of the rapid absorption and the 6-hour half-life, such immediate-release forms result in low levels in the blood by the time of the next administration. It is known to be important to maintain effective myocardial protection throughout the 24-hour period and especially in the early morning when the consequences of ischaemia are most serious. Because complete coverage of the day is not achieved with the immediate-release form, the Applicant has developed a prolonged-release form enabling perfect 24-hour coverage, ensuring a sufficient level in the blood between two administrations whilst retaining a large -2plasma peak after each administration so as to maintain the efficacy of the trimetazidine, maintaining the energy metabolism of a cell exposed to hypoxia or ischaemia and avoiding the lowering of the intracellular level of ATP.
It also allows peripheral vasodilator effects to be avoided, while stabilising blood flow rates and tensional effects.
IE 0 ο 1 0 1 The new formulation according to the invention accordingly allows the positive characteristics of the formulation described in patent PR 2 490 963 to be retained while enabling better coverage of the day, which leads to better compliance and permanent protection.
The present invention relates more especially to a matrix tablet which enables the prolonged release of trimetazidine, or a pharmaceutically acceptable salt thereof) after administration by the oral route and which is composed of a hydrophilic matrix characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer.
This matrix tablet, administrable preferably twice a day, enables prolonged active ingredient release to be obtained whilst retaining a large plasma peak on each administration. It allows plasma levels greater than 70 pg/l to be obtained in humans after each administration and a plasma level greater than or equal to 40 pg/l to be maintained until the next administration, which was not the case with the tablet described in patent FR 2 490 963 when administered 3 times per day.
Among the cellulose derivatives used in the matrix according to the invention, there may be mentioned, more especially, cellulose ethers such as hydroxypropylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, methylcellulose and hydroxypropyl methylcellulose.
The cellulose derivative is preferably hydroxypropyl methylcellulose. The percentage of cellulose derivative polymer is from 25 to 50 % of the total mass of the tablet. -3Hydroxypropyl methylcelluloses that have a viscosity of from 100 cP to 100 000 cP may be used. The preferred viscosity is 4 000 cP.
Various excipients are added to the hydrophilic matrix, for example binders, diluents, lubricants and flow agents. Among the binders, polyvidone is preferably used. The percentage of polyvidone is from 3 to 12 % of the total mass of the tablet. Among the diluents, calcium hydrogen phosphate dihydrate is preferably used, which provides better fluidity and better compressibility than other diluents such as lactose monohydrate. The percentage of calcium hydrogen phosphate is from 25 to 75 % of the total mass of the tablet.
Among the lubricants, there may be mentioned, without implying any limitation, magnesium stearate, stearic acid, glycerol behenate and sodium benzoate. The preferred lubricant is magnesium stearate. Finally, colloidal silica is preferably used as flow agent.
The trimetazidine used in the matrix tablets according to the invention is preferably in the dihydrochloride form.
The percentage of trimetazidine dihydrochloride is from 15 to 30 % of the total mass of the tablet, preferably from 15 to 18 %.
The person skilled in the art will generally consider the release kinetics of matrix tablets to be dependent on the nature and amount of the basic component of the matrix - in this case, namely, the cellulose derivative.
It now appears, surprisingly, that the release kinetics of the matrix tablet according to the invention are influenced neither by the amount nor by the grade of the cellulose derivative used.
Various formulations produced using, on the one hand, hydroxypropyl methylcelluloses of different viscosities and, on the other hand, variable amounts of the same grade of IE Ο 0 1 ο 1 7 -4hydroxypropyl methylcellulose have exhibited equivalent release kinetics, which implies that there exists a specific synergy between the cellulose derivative and the trimetazidine.
The present invention relates also to a process for the preparation of the matrix tablet. The matrix tablet may be prepared by wet granulation followed by compression, by dry granulation followed by compression, or by direct compression. The preparation process is preferably wet granulation followed by compression.
The wet granulation is performed by mixing the trimetazidine, the polyvidone and the diluent, and then wetting that mixture. That first step enables a hydrophilic environment to be created around the active ingredient, which is beneficial for its dissolution, and also enables a unit dose that is as uniform as possible to be obtained.
In a second step, the previously obtained granulate is mixed with the cellulose derivative.
The lubricant and the flow agent are then added to the mixture. The third step is compression of the lubricated mixture previously obtained.
The tablets thus formed are then, if desired, coated according to a conventional coating 15 technique.
The following Examples illustrate the invention but do not limit it in any way. The matrix tablets described in the Examples were prepared in the following manner: - Step A : Mixture of trimetazidine, polyvidone and calcium hydrogen phosphate dihydrate, then wetting of the mixture using a sufficient amount of purified water, granulation and then drying of the granulate.
- StevB: Mixture of the granulate obtained in Step A with hydroxypropyl methylcellulose.
• ‘Steg C : Lubrication of the mixture obtained in Step B with magnesium stearate and colloidal silica. -5-Step D : Compression of the lubricated mixture obtained in Step C on a rotary tablet machine so as to obtain tablets having a hardness of about from 40 to 160 N, measured by breaking across a diameter.
EXAMPLE 1: Formulations of different matrix tablets containing various amounts 5 of trimetazidine Table 1: Unitary formulae for 3 types of tablet Compound Amount (mg) Fj i i F* f3 Trimetazidine dihydrochloride 60 1 30 35 Hydroxypropyl methylcellulose 112 ! 74 ί 74 Polyvidone 13.3 Ϊ 8.7 8.7 Calcium hydrogen phosphate dihydrate 92 ! 85.9 ! 80.9 Magnesium stearate 2.2 ΐ 1 1 Anhydrous colloidal silica 0.5 j 0.4 0.4 Γοία/ mass of ihe tablet 280 1 200 J 200 _ EXAMPLE!: Example 2 shows that different amounts of hydroxypropyl methylcellulose do not have an io influence on the dissolution kinetics of the tablet.
Table 2: Unitary formulae / variable amounts of HPMC Compound Amount (mg) f4 f5 Trimetazidine dihydrochloride 35 35 Hydroxypropyl methylcellulose 54 94 Polyvidone 10.1 7.3 Calcium hydrogen phosphate dihydrate 99.5 62.3 Magnesium stearate 1 1 Anhydrous colloidal silica 0.4 0.4 Total mass of ihe tablet 200 200 Table 3 shows the percentages of compound released as a function of time for the formulations F4 and F5.
IE Ο Ο 1 011 -6Table 3 : Release kinetics Time(h) Percentage of compound released (%) .....*4 Fs 1 41 38 2 59 59 3 80 77 4 97 96 EXAMPLES: Example 3 shows that different grades of hydroxypropyl methylcellulose do not have an influence on the dissolution kinetics ofthe tablet.
Table 4: Formulations / variable grades of HPMC Compound Amount (mg) F3 Fe f7 Trimetazidine dihydrochloride 35 35 35 Hydroxypropyl methylcellulose 4000 cP 74 - - Hydroxypropyl methylcellulose 100 cP - - 74 Hydroxypropyl methylcellulose 100 000 cP - 74 - Polyvidone 8.7 8.7 8.7 Calcium hydrogen phosphate dihydrate 80.9 80.9 80.9 Magnesium stearate 1 1 1 Anhydrous colloidal silica 0.4 0.4 0.4 Table 5 shows the percentages of compound released as a function of time for the formulations F3, Fe and F7.
Table 5: Release kinetics Time (h) Percentage of compound released (%) f3 F6 f7 1 43 41 40 2 62 59 60 3 86 83 83 4 105 102 100 \E0 0 1 0 1 7 -7EXAMPLE 4 : Plasma kinetics study The plasma kinetics were studied after administration of the matrix tablet of formulation F3 described in Example 1 to 12 healthy volunteers.
Administration was carried out for 4 days at the rate of two tablets per day.
The plasma kinetics of the tablet of formula F3 were compared to those of an immediaterelease (IR) tablet administered for 4 days at the rate of three tablets per day.
The unitary formulation of the immediate-release (IR) tablet is as follows: Trimetazidine dihydrochloride............................................................................20 mg Maize starch........................................................................................................26 mg Mannitol.............................................................................................................34 mg Polyvidone............................................................................................................4 mg Magnesium stearate..............................................................................................1 mg Talc.......................................................................................................................5 mg The average plasma concentration is given in Figure 1, which shows the plasma kinetics of trimetazidine, showing average plasma concentrations of trimetazidine (in pg/l) after oral administration of the F3 form and an IR form to 12 healthy volunteers. The curve clearly shows that the F3 form enables prolonged release of trimetazidine to be obtained while retaining a large plasma peak on each administration.
The plasma level observed after each administration is close to 90 pg/l and hardly different from that obtained with the IR form. At the end of 24 hours the plasma level is greater than 40 pg/l whereas, with the immediate-release formulation, it is only about 25 gg/l.
The invention is not limited to the embodiments hereinbefore described which may be varied within the scope of the appended claims.

Claims (17)

CLAIMS ΙΕΟδΗΠ
1.I- Matrix tablet for the prolonged release of trimetazidine or a pharmaceutically acceptable salt thereof, characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer. 5
2. - Matrix tablet according to claim 1, characterised in that the cellulose derivative polymer is a hydroxypropyl methylcellulose.
3. - Matrix tablet according to either claim 1 or claim 2, characterised in that the percentage of cellulose derivative is from 25 to 50 % of the total mass of the tablet.
4. - Matrix tablet according to any preceding claim, characterised in that it also comprises a 10 binder, a diluent, a lubricant and a flow agent.
5. - Matrix tablet according to claim 4, characterised in that the binder is polyvidone.
6. - Matrix tablet according to claim 5, characterised in that the percentage of polyvidone is from 3 to 12 % of the total mass of the tablet.
7. - Matrix tablet according to any one of claims 4, 5 or 6, characterised in that the diluent is 15 calcium hydrogen phosphate dihydrate.
8. - Matrix tablet according to claim 7, characterised in that the percentage of calcium hydrogen phosphate dihydrate is from 25 to 75 % of the total mass of the tablet.
9. - Matrix tablet according to any one of claims 4, 5, 6, 7 or 8, characterised in that the lubricant is magnesium stearate and the flow agent is anhydrous colloidal silica. -910- Matrix tablet according to any preceding claim, characterised in that the trimetazidine is in the dihydrochloride form.
10. 11- Matrix tablet according to claim 10, characterised in that the percentage of trimetazidine dihydrochloride is from 15 to 30 % of the total mass of the tablet.
11. 12- Matrix tablet according to claim 10 or 11 characterised in that the percentage of trimetazidine dehydrochloride is from 15 to 18% of the total mass of the tablet.
12. 13- Matrix tablet according to any of claims 10 to 12, characterised in that the percentage of trimetazidine dihydrochloride is 17.5 % of the total mass of the tablet.
13. 14- Matrix tablet according to any preceding claim, characterised in that it contains 35 mg of trimetazidine dihydrochloride, 74 mg of hydroxypropyl methylcellulose, 8.7 mg of polyvidone, 80.9 mg of calcium hydrogen phosphate dihydrate, 1 mg of magnesium stearate and 0.4 mg of anhydrous colloidal silica.
14. 15- Matrix tablet according to claim 14, characterised in that it is administered twice per day.
15. 16- Matrix tablet according to any preceding claim, characterised in that it enables plasma levels greater than 70 μg/1 to be obtained in humans after each administration and a plasma level greater than or equal to 40 pg/l to be maintained until the next administration.
16. 17- Process for the preparation of a matrix tablet according to any one of claims 1 to 14, characterised in that: - wet granulation is carried out by mixing trimetazidine, polyvidone and the diluent and then wetting that mixture, - the granulate thus obtained is mixed with the cellulose derivative, - the lubricant and the flow agent are then added, - the previous mixture is then compressed. -1018-Matrix tablet according to any one of claims 1 to 16 for use in the prophylactic treatment of angina pectoris, in chorioretinal attacks and in the treatment of vertigo of vascular origin. 5 19- A matrix tablet substantially as hereinbefore described with reference to the examples and drawings.
17. 20- A process for the manufacture of a matrix tablet substantially as hereinbefore described with reference to the examples and drawings. CRUICKSHANK & CO.
IE20001017A 1999-12-17 2000-12-15 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route IE20001017A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915960A FR2802424B1 (en) 1999-12-17 1999-12-17 MATRIX TABLET FOR THE EXTENDED RELEASE OF TRIMETAZIDINE AFTER ORAL ADMINISTRATION

Publications (1)

Publication Number Publication Date
IE20001017A1 true IE20001017A1 (en) 2002-04-03

Family

ID=9553398

Family Applications (1)

Application Number Title Priority Date Filing Date
IE20001017A IE20001017A1 (en) 1999-12-17 2000-12-15 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route

Country Status (33)

Country Link
EP (1) EP1108424B2 (en)
JP (2) JP2001172181A (en)
KR (1) KR100456933B1 (en)
CN (1) CN1166408C (en)
AR (1) AR026968A1 (en)
AT (1) ATE296622T1 (en)
AU (1) AU780011B2 (en)
BG (1) BG65773B1 (en)
BR (1) BR0005915A (en)
CY (1) CY2347B1 (en)
CZ (1) CZ299461B6 (en)
DE (1) DE60020501T3 (en)
DK (1) DK1108424T4 (en)
EA (2) EA008223B1 (en)
ES (2) ES2176106B1 (en)
FR (1) FR2802424B1 (en)
GE (1) GEP20053540B (en)
GR (1) GR1003658B (en)
HK (1) HK1036937A1 (en)
HU (1) HU226956B1 (en)
IE (1) IE20001017A1 (en)
IT (1) IT1317075B1 (en)
LU (1) LU90700B1 (en)
MX (1) MXPA00012462A (en)
NZ (1) NZ508912A (en)
OA (1) OA12121A (en)
PL (1) PL206994B1 (en)
PT (2) PT1108424E (en)
SI (1) SI1108424T2 (en)
SK (1) SK286752B6 (en)
UA (1) UA80087C2 (en)
WO (1) WO2001043747A1 (en)
ZA (1) ZA200007548B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1195160E (en) * 2000-10-05 2009-12-07 Usv Ltd Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
WO2005011682A1 (en) * 2003-08-04 2005-02-10 Kyorin Pharmaceutical Co., Ltd. Sustained release tablet for oral use
SG126792A1 (en) * 2005-04-27 2006-11-29 Servier Lab Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
FR2885807B1 (en) * 2005-05-18 2008-05-16 Mg Pharma SOLID PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF 1- (2,3,4-TRIMETHOXYBENZYL) PIPERAZINE, AND PREPARATION METHOD
CZ300307B6 (en) * 2006-01-04 2009-04-15 Zentiva, A. S. Modified release tablet containing trimetazidine or pharmacologically acceptable salts thereof
EA009776B1 (en) * 2006-07-18 2008-04-28 Мераб Ревазович Кокеладзе Method for preparing tablets of dihydrochloride trimethazine and composition thereof
EA009810B1 (en) * 2006-12-26 2008-04-28 Закрытое Акционерное Общество "Канонфарма Продакшн" Matrix for manufacturing tableted dosage form and method of treatment
WO2009034541A2 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
EP2389167A2 (en) 2009-01-20 2011-11-30 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
ES2567722T3 (en) * 2009-01-30 2016-04-26 Lupin Limited Trimetazidine pharmaceutical compositions
TR201001902A2 (en) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Trimetazidine tablets with extended release
RU2445958C2 (en) * 2010-04-20 2012-03-27 Общество с ограниченной ответственностью "Озон" (ООО "Озон") Matrix tablet with trimetazidine prolonged-release base and method for preparing it
EP2394644B1 (en) 2010-05-04 2014-07-09 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Trimetazidine Formulation With Different Release Profiles
EP2386302A1 (en) 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
FR2978916B1 (en) * 2011-08-10 2013-07-26 Servier Lab SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN
FR2986431B1 (en) * 2012-02-03 2017-03-17 Servier Lab PROLONGED RELEASE OF TRIMETAZIDINE PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PRODUCTION THEREOF AND USE IN THERAPEUTIC TREATMENTS
CN102824644B (en) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 High-stability sustained-release tablet prepared by using hydroxy propyl cellulose
KR20160118733A (en) 2015-04-03 2016-10-12 이인현 Hose guide apparatus for hose winder and hose winder
CN109316455B (en) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 Trimetazidine hydrochloride sustained release tablet
CN109908096A (en) * 2017-12-12 2019-06-21 武汉武药科技有限公司 A kind of trimetazidine hydrochloride sustained-release tablets and preparation method thereof
WO2024218267A2 (en) * 2023-04-20 2024-10-24 Les Laboratoires Servier Novel trimetazidine solid phases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
FR2490963B1 (en) * 1980-09-30 1986-04-18 Science Union & Cie NOVEL THERAPEUTIC COMPOSITION WITH ANTI-ISCHEMIC ACTION CONTAINING TRIMETHOXY 2, 3, 4-BENZYL 1-PIPERAZINE
KR850006132A (en) * 1984-02-29 1985-10-02 진 크라메르, 한스 루돌프 하우스 Bromocriptine Composition
JPS61293931A (en) * 1985-06-24 1986-12-24 Teijin Ltd Slow-releasing pharmaceutical composition
JPH0625055B2 (en) * 1985-03-18 1994-04-06 日本ケミフア株式会社 Persistent tablets
EP0207638B1 (en) * 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
SE455836B (en) * 1985-10-11 1988-08-15 Haessle Ab PREPARATION WITH CONTROLLED RELEASE CONTAINING A SALT OF METOPROLOL AND METHOD FOR PREPARING THIS PREPARATION
SE8601624D0 (en) * 1986-04-11 1986-04-11 Haessle Ab NEW PHARMACEUTICAL PREPARATIONS
FR2677886B1 (en) * 1991-06-18 1995-03-31 Adir MATRIX TABLET FOR THE EXTENDED RELEASE OF INDAPAMIDE AFTER ORAL ADMINISTRATION.
FR2681324B1 (en) * 1991-09-18 1993-10-29 Adir Cie NOVEL TRIMETAZIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR940021051A (en) * 1993-03-03 1994-10-17 손정삼 3-step drug release sustained tablet
RU2082400C1 (en) * 1993-12-16 1997-06-27 Акционерное общество - Фармацевтическая фирма "Ник-Фарм" Method of nitroglycerol prolonged action preparing
FR2717687B1 (en) * 1994-03-24 1996-06-14 Adir Pharmaceutical compositions for the sustained release of trimetazidine after oral administration.

Also Published As

Publication number Publication date
CZ299461B6 (en) 2008-08-06
MXPA00012462A (en) 2002-06-04
KR20010062478A (en) 2001-07-07
AU7228500A (en) 2001-06-21
SK286752B6 (en) 2009-04-06
HK1036937A1 (en) 2002-01-25
PT102542A (en) 2001-06-29
EA008223B1 (en) 2007-04-27
DE60020501D1 (en) 2005-07-07
EA200501901A1 (en) 2006-06-30
ZA200007548B (en) 2001-06-19
PL206994B1 (en) 2010-10-29
WO2001043747A8 (en) 2001-09-07
WO2001043747A1 (en) 2001-06-21
KR100456933B1 (en) 2004-11-10
LU90700B1 (en) 2007-12-03
BR0005915A (en) 2001-10-02
HU226956B1 (en) 2010-03-29
CZ20022082A3 (en) 2002-09-11
JP2007314578A (en) 2007-12-06
AU780011B2 (en) 2005-02-24
ES2176106B1 (en) 2004-01-16
ITRM20000667A1 (en) 2002-06-14
SI1108424T1 (en) 2005-10-31
FR2802424B1 (en) 2002-02-15
ATE296622T1 (en) 2005-06-15
ITRM20000667A0 (en) 2000-12-14
EA200001201A3 (en) 2001-10-22
SI1108424T2 (en) 2014-02-28
BG65773B1 (en) 2009-11-30
CY2347B1 (en) 2004-06-04
DK1108424T3 (en) 2005-10-03
ES2176106A1 (en) 2002-11-16
DK1108424T4 (en) 2013-12-16
ES2240033T3 (en) 2005-10-16
EP1108424A1 (en) 2001-06-20
JP2001172181A (en) 2001-06-26
AR026968A1 (en) 2003-03-05
ES2240033T5 (en) 2014-01-16
FR2802424A1 (en) 2001-06-22
GR1003658B (en) 2001-09-05
HUP0004966A3 (en) 2008-04-28
EA200001201A2 (en) 2001-08-27
HUP0004966A2 (en) 2002-06-29
DE60020501T2 (en) 2006-04-27
DE60020501T3 (en) 2014-03-20
PL344564A1 (en) 2001-06-18
EP1108424B1 (en) 2005-06-01
OA12121A (en) 2003-10-20
CN1302663A (en) 2001-07-11
EP1108424B2 (en) 2013-09-04
BG106927A (en) 2003-05-30
HU0004966D0 (en) 2001-02-28
GEP20053540B (en) 2005-06-10
SK8632002A3 (en) 2002-10-08
CN1166408C (en) 2004-09-15
IT1317075B1 (en) 2003-05-26
PT1108424E (en) 2005-08-31
NZ508912A (en) 2002-04-26
UA80087C2 (en) 2007-08-27

Similar Documents

Publication Publication Date Title
AU780011B2 (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
EP1274402B1 (en) Pharmaceutical composition for the controlled release of paracetamol
GB2209940A (en) Sustained release etodolac
AU2001260212A1 (en) Composition
HUT72635A (en) Compositions containing alfuzonin-hydrochloride of sustained release
CA1272957A (en) Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine
JPH0757726B2 (en) Sustained release tablets based on high molecular weight hydroxypropyl methylcellulose
WO2005011666A1 (en) Stable sustained release oral dosage form of gabapentin
US7767227B2 (en) Galenical form for oral administration with prolonged release of molsidomine
WO2020148217A1 (en) A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
Narla et al. Formulation and evaluation of sustained release metoprolol succinate matrix tablets by direct compression process by using Kollidon SR
WO2000013675A1 (en) Methazolamide compositions and method of use
EP1406635A2 (en) A controlled release anti-inflammatory formulation and a process for the preparation thereof

Legal Events

Date Code Title Description
FC9A Application refused sect. 31(1)